来自MSN1 个月
GSK reports positive outcomes from Phase III multiple myeloma treatment trial
GSK has announced positive headline interim analysis outcomes from a Phase III trial, which is evaluating Blenrep (belantamab mafodotin) along with bortezomib and dexamethasone (BorDex ...
pharmaphorum5 天
ASH: Blenrep ups survival by 42% in multiple myeloma trial
The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with Darzalex plus BorDex (DVd) regimen, with the difference between the two ...
pharmaphorum5 个月
GSK files Blenrep in EU, seeking return to market
The marketing application to the EMA covers Blenrep (belantamab mafodotin) in combination with bortezomib plus dexamethasone (BorDex) or pomalidomide plus dexamethasone (PomDex) as a treatment for ...